Ridge Biotechnologies raises $25 million in seed financing to enhance AI-enabled precision enzyme and drug design, led by Sutter Hill Ventures.

Sep 09, 2025•3 days ago

Amount Raised

$25 Million

Round Type

seed

Palo AltoArtificial IntelligenceBiotechnologyHealth Care

Investors

Overlap HoldingsSutter Hill Ventures

Description

Ridge Biotechnologies has emerged from stealth with an oversubscribed $25 million in seed financing. The round was led by Sutter Hill Ventures, with participation from Overlap Holdings. The funding will support the rollout of its NativeLink and ProTrigger products. Ridge Bio aims to develop cutting-edge therapeutics using machine learning and bioengineering.

Company Information

Company

Ridge Biotechnologies

Location

Palo Alto, California, United States

About

Ridge Biotechnologies is a pioneering company focused on AI-enabled precision enzyme and targeted drug design. The company aims to revolutionize drug development through advanced machine learning and bioengineering techniques. Their innovative platform enables the design of therapeutics that address complex drug development challenges, promising safer and more precise medicines. Ridge Bio has launched products such as NativeLink and ProTrigger, enhancing therapeutic applications in antibody-drug conjugates.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends